STOCK TITAN

Lantern Pharma Inc - LTRN STOCK NEWS

Welcome to our dedicated news page for Lantern Pharma (Ticker: LTRN), a resource for investors and traders seeking the latest updates and insights on Lantern Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lantern Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lantern Pharma's position in the market.

Rhea-AI Summary
Lantern Pharma Inc. (NASDAQ: LTRN) announced operational highlights and financial results for the fourth quarter and fiscal year ended December 31, 2023. The company is actively engaged in multiple clinical trials for AI-guided drug candidates, with first data expected in the second half of 2024. Lantern Pharma has dosed initial patients in Phase 1 clinical trials for synthetic lethal drug-candidates LP-184 and LP-284, expanded Phase 2 LP-300 Harmonic™ clinical trial, and advanced Starlight Therapeutics towards a potential Phase 1B/2 clinical trial. The company exceeded its 2023 goal for oncology drug development AI platform RADR® and aims to achieve a 100 billion datapoint goal for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.8%
Tags
earnings
-
Rhea-AI Summary
Lantern Pharma Inc. (NASDAQ: LTRN) announces dosing of first two patients in Phase 1 clinical trial for LP-284, a potential therapy for non-Hodgkin’s lymphoma and solid tumors. LP-284 is the second synthetic-lethal molecule from Lantern, with AI playing a crucial role. The drug has the potential to benefit 40,000 to 80,000 patients annually, with a global market potential of $4 billion USD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.37%
Tags
clinical trial AI
-
Rhea-AI Summary
Lantern Pharma Inc. (NASDAQ: LTRN) will host a webcast to discuss its fourth quarter and fiscal year 2023 financial results, along with upcoming milestones, clinical trials, and developments of its AI platform, RADR®.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.58%
Tags
conferences earnings
Rhea-AI Summary
Lantern Pharma (NASDAQ: LTRN) will present at a virtual conference hosted by HCW on March 7th. CEO Panna Sharma will discuss AI-driven cancer drug discovery. Investors can register for the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.95%
Tags
conferences
-
Rhea-AI Summary
Lantern Pharma Inc. (NASDAQ: LTRN) announces significant milestones in the growth and development of its RADR® AI platform for cancer drug discovery. The platform has exceeded 60 billion data points and is expected to reach 100 billion by 2024. Lantern focuses on enhancing data growth efforts in drug sensitivity, combination treatment outcomes, biomarker data in rare cancers, and synthetic lethal targets. The company aims to improve molecular optimization, feature extraction, and drug-drug interaction predictions. RADR®'s expansion enables more precise cancer therapy development, automating data collection, and curation processes efficiently.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.4%
Tags
none
-
Rhea-AI Summary
Lantern Pharma Inc. (NASDAQ: LTRN) achieves a significant milestone in its ADC program by developing a novel cryptophycin-based ADC with potent anti-tumor activity. The company collaborates with academic partners to create highly specific and effective ADCs for various solid tumor indications. Leveraging RADR® AI platform and a unique conjugation approach, Lantern aims to advance towards IND development in 2024, targeting unresponsive solid tumors. The cryptophycin ADC shows superior potency and tumor-killing capabilities compared to existing ADCs, offering a promising solution for cancer therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
none
Rhea-AI Summary
Starlight Therapeutics, a Lantern Pharma subsidiary, has announced the appointment of Marc Chamberlain, M.D. as its Chief Medical Officer. Dr. Chamberlain will oversee clinical operations and planned clinical trials for brain cancers. He brings extensive expertise in neuro-oncology and therapeutic development, which will be invaluable for advancing Starlight's AI-enabled and accelerated drug development portfolio. Starlight is focused on developing precision therapeutics for cancers with limited or no effective therapeutic options, such as pediatric and adult brain cancers. The company is preparing for recurrent glioblastoma studies and has developed a CNS penetrant wholly synthetic acylfulvene, LP-184, for targeting brain tumors. The announcement marks a significant step in the company's mission to transform oncology with AI-enabled drug development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.6%
Tags
none
-
Rhea-AI Summary
Lantern Pharma Inc. (NASDAQ: LTRN) has received Orphan Drug Designation (ODD) for LP-284 from the U.S. FDA for the treatment of high-grade B-cell lymphoma with MYC and BCL2 rearrangements. The drug has shown potent anti-tumor activity in preclinical models and is being developed for several aggressive B-cell NHL, including MCL and HGBL. LP-284 received its second ODD this year, making a total of five orphan designations granted to Lantern. The ODD provides seven years of market exclusivity and eligibility for expedited drug development programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.02%
Tags
clinical trial
-
Rhea-AI Summary
Lantern Pharma Inc. (NASDAQ: LTRN) announced FDA clearance for Phase 1 clinical trial for LP-284 in non-Hodgkin’s lymphomas, progress in Phase 2 LP-300 trial for lung cancer, and financial results for Q3 2023. The company's AI platform RADR® aims to revolutionize cancer drug development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.21%
Tags
earnings
Rhea-AI Summary
Lantern Pharma Inc. (NASDAQ: LTRN) will host its third quarter 2023 operating and financial results webcast on November 8th at 4:30 p.m. ET. The company will discuss the operating and financial results for the third quarter, as well as provide guidance on upcoming milestones, clinical trials, and developments of its AI platform, RADR®. The webcast will be led by Panna Sharma, President and CEO of Lantern Pharma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.23%
Tags
conferences earnings
Lantern Pharma Inc

Nasdaq:LTRN

LTRN Rankings

LTRN Stock Data

94.52M
7.86M
15.06%
22.56%
1.35%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Dallas

About LTRN

lantern pharma is leading a wave of innovation in cancer treatment that we believe will bring the best therapies to patients who are most likely to respond. we are pioneering precision medicine approach to cancer by tailoring promising drug programs to the right patients. our approach is to use biomarker based genetic screening to identify and treat patients that would benefit most from our drugs. we believe this approach will reduce the cost of development and increase the speed to market. our strategy is to acquire or partner with promising drug and diagnostic companies to move forward promising personalized medicine programs for cancer patients.